ArticleRisk management and healthcare policy2025
Global and Regional Trends in Autism Burden from 1990 to 2021: A Data Re-Analysis and Prediction from the Global Burden of Disease Study.
Article in Risk management and healthcare policy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Analysis of the global burden, biological risk factors, and implications of autism spectrum disorder.Pediatric research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to investigate global incidence rates and disability-adjusted life-years (DALYs) for autism spectrum disorder (ASD) from 1990 to 2021 and forecast trends for the next 25 years. Methods: Utilizing data from the Global Burden of Disease (GBD) study, we examined global and country-specific ASD incidence, prevalence, and burden. We also calculated age-standardized prevalence, analyzed by sex, age groups, sociodemographic index (SDI) regions, and GBD regions, and made predictions for the future. Results: In 2021, the GBD reported global age-standardized ASD incidence and prevalence at 0.019% and 0.788%, respectively. High-income Asia-Pacific had the highest burden, while Tropical Latin America had the lowest. From 1990 to 2021, global age-standardized prevalence rose by 1.95%, and incidence by 5.20%. Females and low-middle SDI regions saw the most significant increases in incidence, while the Caribbean and Serbia saw decreases. High-income Asia Pacific and Japan experienced the largest prevalence increases, and Middle SDI, East Asia, high-income Asia Pacific, and Equatorial Guinea saw the most significant DALY increases, with Oceania showing the largest decrease. Predictive models forecast continued increases in incidence, prevalence, and DALYs from 2022 to 2046. Conclusion: ASD incidence, prevalence, and DALYs are rising annually, with notable increases in females and middle-low income countries and a decline in the Caribbean. Tailored screening and interventions based on regional rates are essential for improving the health of individuals with autism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.